Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-UMIN000052238
JPRN-UMIN000052238CompletedUnknown

Immune Persistence and Safety Survey regarding Initial and Booster Vaccination of Monovalent Vaccine for SARS-CoV-2 Omicron Strain XBB.1.5 (Cohort Study) in Japan - Immune Persistence and Safety Cohort Survey on SARS-CoV-2 XBB Strain Initial and Booster Vaccination in Japan

Juntendo University0 sites3,391 target enrollmentStarted: September 20, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Unknown
Status
Completed
Enrollment
3,391
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
12years-old to ot applicable (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •Those who are inappropriate as the subject of the survey determined by the principal investigator

Investigators

Similar Trials

Completed
Unknown
Immune Persistence and Safety Survey (Cohort Survey) related to the Bivalent SARS-CoV-2 Booster Vaccination in JapaCOVID-19
JPRN-UMIN000049533Juntendo University2,848
Completed
Not Applicable
Immune Persistence and Safety Survey (Cohort Survey) related to the SARS-CoV-2 Booster Vaccination (4th dose) in JapaCOVID-19
JPRN-UMIN000047919Juntendo University3,441
Completed
Unknown
Immune Persistence and Safety Cohort Survey on Booster vaccination of the Newly developed SARS-CoV-2 Omicron Strain XBB.1.5 Vaccine in JapaCOVID-19
JPRN-UMIN000053072Juntendo University300
Completed
Not Applicable
Immune persistence and safety survey (cohort survey) related to the first series of new corona recombinant protein vaccines and boostersCOVID-19
JPRN-UMIN000047920Juntendo University579
Active, not recruiting
Phase 1
Immunogenicity and Safety of the Investigational Inactivated, Split-Virion Influenza Vaccine 15 µg Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip® in 50 to 59 Years old AdultsVaccination of adults subjects aged 50 to 59 years with inactivated, split-virion influenza vaccine administered by the intradermal route using Vaxigrip® as IM reference vaccine.
EUCTR2008-001219-39-NLSanofi Pasteur SA2,740